New method finds compounds that bind and inhibit individual members of a family of key regulatory proteins, called cyclophilins, that have been difficult to target selectively.
Researchers take a broad, multi-faceted look at a large collection of cancer cell lines, creating a new trove of data to explore for drug development opportunities.
Chordoma is literally a one in a million cancer, with few effective treatment options. A new understanding of the biology behind this tumor type is bringing novel opportunities to light.